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Abstract 
Shiga toxin (Stx)-producing Escherichia coli (STEC) leads to food poisoning by causing hemorrhagic colitis and hemo-
lytic uremic syndrome. Some STEC produce Shiga toxin 1 (Stx1) and/or Shiga toxin 2 (Stx2), a relatively stable protein 
toxin, necessitating the development of an efficient inactivation method. Here we applied a nitrogen gas plasma 
apparatus to the inactivation of Stx. Samples of Stx1 and Stx2 were treated with a nitrogen gas plasma generated 
by a plasma device using a short high-voltage pulse applied by a static induction thyristor power supply at 1.5 kpps 
(kilo pulse per second). The recovered Stx samples were then analyzed for immunological and biological activities. 
Immunochromatography demonstrated that Stx1 and Stx2 were degraded by the gas plasma. Quantification by 
enzyme-linked immunosorbent assay (ELISA) showed that both toxins were efficiently degraded to less than 1/10th 
of their original concentration within 5 min of treatment. Western blotting further showed the gas plasma treatment 
degraded the A subunit, which mediates the toxicity of Stx. Moreover, an assay using HEp-2 cells as an index of cyto-
toxicity showed that gas plasma treatment reduced the toxic activity of Stx. Therefore, nitrogen gas plasma might be 
an efficient method for the inactivation of Stx.
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Introduction
The virulence of Shiga toxin (Stx)-producing Escherichia 
coli (STEC), such as E. coli O157:H7 and other serotypes, 
including their most dangerous subset, enterohemor-
rhagic E. coli (EHEC), depends on the production of Stx 
(Gyles 2007; Hunt 2010). The toxins inhibit protein syn-
thesis and are therefore deleterious to humans, leading to 
life-threating complications including hemorrhagic coli-
tis (HC) and hemolytic uremic syndrome (HUS) (Boer-
lin et  al. 1999; Scallan et  al. 2011). These illnesses are 
known as food-borne diseases, resulting from the inges-
tion of food contaminated with STEC and their toxins. 
To improve the quality and safety of the food supply, it is 
necessary to minimize toxic compounds in foods. Thus, 
technologies to degrade and/or inactivate Stx are needed.
Stx produced by STEC comprise two major groups; 
namely, Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2). Stx1 
has identical characteristics to Stx produced by Shigella 
dysenteriae in terms of immunological, physical, chemi-
cal, and biological properties (Takao et  al. 1988). Stx2 
has 55% nucleotide sequence identity to Stx1 but differs 
substantially in its physiological properties (Jackson et al. 
1987; Scotland et al. 1985). Stx1 and Stx2 each comprise 
an A subunit monomer, which plays a role in toxicity, and 
a pentamer of B subunits, which are involved in binding 
to a cellular receptor, globotriaosylceramide (Gb3) (Ling-
wood et al. 1987; Stein et al. 1992; Fraser et al. 1994). Stx2 
is known to be highly virulent, and is several orders of 
magnitude more toxic than Stx1 (Nataro and Kaper 1998; 
Pickering et al. 1994; Manning et al. 2008). Furthermore, 
Stx2 is relatively heat stable and is not inactivated by pas-
teurization (Rasooly and Do 2010).
Several compounds have been reported to inhibit Stx1 
and Stx2 (Sugita-Konishi et al. 1999; Kulkarni et al. 2010; 
Rasooly et al. 2010; Quinones et al. 2009; Friedman et al. 
2013). However, it remains unclear whether these anti-
Stx1 and anti-Stx2 compounds cause irreversible inac-
tivation or whether they have indirect effects, such as 
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inhibiting toxin release or affecting the digestive tract of 
the host (Friedman and Rasooly 2013).
Recently, the effectiveness of gas plasma technology 
in eradicating various types of microbes such as viruses, 
bacteria and fungi has been demonstrated (Fridman 2012; 
Laroussi et al. 2012; Shintani et al. 2010). In this regard, 
gas plasma technology is a promising method for achiev-
ing disinfection and sterilization in a broad range of appli-
cations. In particular, gas plasma technology provides an 
excellent platform for food control, preventing the spread 
of harmful microbes. For example, Schlüter’s group has 
demonstrated inactivation of Stx-producing E. coli using 
an atmospheric pressure plasma jet (Baier et al. 2015).
The gas plasma can be artificially generated by various 
types of discharge, including arc, corona, direct current, 
glow, high/low frequency, micro, pulse, and streamer. 
Further developments in gas plasma technology are likely 
to enable broader applications including the detoxifica-
tion of toxins. Although Park’s group and others have 
worked on the inactivation of lipopolysaccharide using a 
different technology for producing gas plasma (Park et al. 
2007; Shintani et al. 2007), there are no reports showing 
the inactivation of Stx using gas plasma.
Recently, we successfully generated nitrogen gas 
plasma by applying a short-time high-voltage pulse to 
nitrogen gas as an inert gas, using a static induction (SI) 
thyristor power supply (Sakudo et  al. 2013a). Bacterial 
spores, vegetative bacteria, and viruses are all inactivated 
by the nitrogen gas plasma (Sakudo et  al. 2014; Maeda 
et al. 2015). Several factors contribute to the thermal and 
non-thermal mechanism of inactivation, such as heat, 
ultraviolet (UV) radiation, and reactive chemical species 
generated during operation of the nitrogen gas plasma 
device. Among them, reactive chemical species may be 
the most important factor for inactivation of bacteria and 
viruses (Maeda et al. 2015; Sakudo et al. 2017).
Here, based on these previous observations, we have 
extended our research to examine the potential use of 
nitrogen gas plasma for the inactivation of Stx. The effect 
of nitrogen gas plasma treatment on Stx was investigated 
by biochemical analyses and a bioassay using cell culture. 
The potential mechanisms of Stx inactivation by the gas 
plasma are then discussed.
Materials and methods
Exposure of Stx samples to gas plasma
Stx1 from E. coli O157:H7 and Stx2 from E. coli 
O157:H7, which were solubilized at 0.1 mg/ml in 0.1 M 
Tris–HCl buffer (pH 8.6), 0.1  M NaCl, 0.001% polyvi-
nyl alcohol after purification by affinity chromatography 
using Gb3 and 0.45  μm filtration, were purchased from 
Nakalai Tesque (Kyoto, Japan). The Stx1 and Stx2 solu-
tions were each diluted with phosphate-buffered saline 
(PBS) to 1 μg/ml, and a 20 μl aliquot was dropped onto 
a coverslip (24  mm  ×  60  mm Thickness No. 1, 0.12–
0.17  mm, Matsunami Glass Industries, Ltd., Osaka, 
Japan) and air-dried. The nitrogen gas plasma was pro-
duced by a BLP-TES (bi-polar and low-pressure plasma-
triple effects sterilization) device (NGK Insulators, Ltd.) 
using a short-time high-voltage pulse generated by an SI 
thyristor, which was used as a pulsed power supply. The 
coverslip containing the Stx samples was placed in the 
device’s chamber on a grid of electrodes, comprising a 
cathode electrode (earth electrode) between two anode 
electrodes (high voltage electrodes). The chamber box 
was then decompressed and degassed, and nitrogen gas 
(99.9995%, Okano, Okinawa, Japan) was introduced at a 
flow rate of approximately 10 L/min. The pressure in the 
box was maintained at about 0.5 atmospheres, and the 
plasma was discharged at 0–1.5 kpps (kilo pulse per sec-
ond). Nitrogen gas plasma-treated and control untreated 
samples were recovered from the coverslip by reconstitu-
tion in 20 μl of PBS. The recovered solutions were sub-
jected to biochemical and immunological analysis.
Immunochromatography
Stx1 and Stx2 in the recovered samples were detected 
by immunochromatography using the NH Immuno-
chromato VT1/2 kit (NH Foods Ltd., Osaka, Japan) in 
accordance with the manufacturer’s instructions. The 
kit produces two lines: development of a control line 
indicates that the strip has functioned properly, whereas 
development of a test line indicates the presence of Stx1 
or Stx2. The kit can detect Stx1 at 2.5 ng/ml, and Stx2 at 
1.25 ng/ml (Yonekita et al. 2012).
Enzyme‑linked immunosorbent assay (ELISA)
Stx1 and Stx2 in the recovered samples were quanti-
fied by using an ELISA kit,  RIDASCREEN® Verotoxin 
(R-Biopharm AG, Darmstadt, Germany) in accordance 
with the manufacturer’s instructions. The concentration 
of Stx1 and Stx2 was quantified by measuring absorbance 
at 450 nm relative to respective Stx1 and Stx2 standards.
Calculation of the detection limit
The limit of detection in the ELISA was calculated accord-
ing to Miller’s study (Miller and Miller 2010). Equation 1 
defines the detection limit (y), which indicates whether a 
sample contains a certain Stx based on the average (yB) 
and standard deviation  (SB) of the signal from a blank 
control (signal of samples without Stx). The calculated 
intercept is used as an estimate of yB. Equation 2 is used 
to estimate  SB, or statistics  Sy/x, which estimates the ran-
dom error in the y direction (Miller and Miller 2010). The 
ŷi values are the points corresponding to the individual x 
values on the calculated regression line:
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Western blotting
Each recovered sample was added to an equal volume 
of 2×  sodium dodecyl sulfate (SDS) gel-loading buffer 
[90  mM Tris–HCl (pH 6.8), 10% mercaptoethanol, 2% 
SDS, 0.02% bromophenol blue, and 20% glycerol] and 
boiled for 5  min. The proteins were then resolved by 
SDS–polyacrylamide gel electrophoresis (PAGE) before 
being electroblotted onto a polyvinylidene difluoride 
(PVDF) membrane (Hybond-P; Amersham-Pharmacia 
Biotech, Piscataway, NJ, USA) for 60 min at 15 V. Blots 
were treated with 5% skimmed milk for 1  h at room 
temperature and then incubated with a rabbit poly-
clonal anti-Stx1 antibody (Cat No. 64-025, BioAcademia, 
Osaka, Japan) or a mouse monoclonal anti-Stx2 antibody 
(Cat No. 20273-04, Nakalai Tesque) in PBS contain-
ing 0.1% Tween 20 (PBS-T) and 0.5% skimmed milk for 
1 h at room temperature. After three washes with PBS-
T, the membrane was incubated in horseradish peroxi-
dase (HRP)-conjugated anti-rabbit IgG or anti-mouse 
IgG (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA, USA) in PBS-T and 0.5% skimmed milk for 
1 h at room temperature. After three washes with PBS-T, 
the proteins were detected by using an enhanced chemi-
luminescence detection kit (Amersham-Pharmacia Bio-
tech) and an Ez-Capture MG imaging system (ATTO 
Corp., Tokyo, Japan).
Cell assay
The activity of Stx1 and Stx2 was measured by previ-
ously described methods (Jones et  al. 2000) with slight 
(1)y = yB + 3SB
(2)Sy/x =
{∑




modification. In brief, the index of cytotoxic activity of 
Stx1 and Stx2 was measured in HEp-2 cells, cultured in 
Minimum Essential Medium (MEM) containing 10% 
fetal calf serum (FCS). The recovered Stx samples were 
50-fold diluted with serum-free MEM and then added to 
1 × 104 HEp-2 cells at 100 μl/well in a 96-well microti-
ter plate. After incubation at 37 °C for 24 h for Stx1 and 
for 48  h for Stx2, cell viability was measured by using 
the Cell Counting kit-8 (Dojindo, Kumamoto, Japan). In 
accordance with the manufacturer’s instructions, 10 μl of 
cell counting kit-8 solution was added to the microplate, 
which was then incubated at 37  °C in 5%  CO2. Absorb-
ance was determined at 450  nm relative to a reference 
wavelength of 630 nm using a microplate reader (Model 
680; Bio-Rad, Hercules, CA, USA).
Statistical analysis
Results are reported as the mean ±  standard deviation. 
Statistical analysis of differences was performed by non-
repeated measures analysis of variance (ANOVA), fol-
lowed by the Bonferroni correction.
Results
To investigate the effect of nitrogen gas plasma on Stx, 
20  μl of a 1  μg/ml solution of Stx1 or Stx2 was spotted 
onto a coverslip, which was placed on the earth electrode 
of the BLP-TES device, and subjected to nitrogen gas 
plasma treatment (1.5  kpps, 0, 5, 15, and 30  min). Stx1 
and Stx2 were then recovered from the treated spots, and 
subjected to various analyses.
First, the treated Stx1 and Stx2 were subjected to 
immunochromatography (Fig.  1). The results showed 
that the test lines of Stx1 were diminished by gas plasma 
treatment for 5, 15 and 30  min, as compared with the 
untreated sample (0  min) (Fig.  1a). In the case of Stx2, 
Fig. 1 Immunochromatography of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) after nitrogen gas plasma treatment. A coverslip containing dried 
spots from 20 μl aliquots of a 1 μg/ml solution of Shiga toxins (Stx) including Stx1 (a) and Stx2 (b) was treated with nitrogen gas plasma using a 
bi-polar and low-pressure plasma-triple effects sterilization (BLP-TES) device (1.5 kpps) for 0, 5, 15, or 30 min. The recovered Stx1 and Stx2 samples 
were analyzed by immunochromatography using an NH immunochromato VT1/2 kit (NH Foods Ltd., Osaka, Japan). Test lines for Stx1 and Stx2, and 
reference lines for the internal control are indicated by arrows
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test lines were detected in the untreated sample (0 min) 
and the sample treated for 5 min, but were diminished in 
samples treated for 15 and 30 min (Fig. 1b).
Next, the gas plasma-treated Stx1 and Stx2 sam-
ples were subjected to ELISA (Fig.  2), which provides a 
quantitative and more sensitive and accurate analysis 
than immunochromatography. The detection limit of 
the ELISA was calculated to be 0.3279  ng/ml for Stx1 
and 0.6540  ng/ml for Stx2. The results of the ELISA 
(mean  ±  standard deviation) showed that the treat-
ment of Stx1 and Stx2 with nitrogen gas plasma at 
1.5  kpps decreased the toxin levels by more than 90%: 
Stx1 decreased from 351.98  ±  19.20  ng/ml at 0  min 
of treatment to 21.24  ±  0.65  ng/ml at 5  min of treat-
ment, and Stx2 decreased from 633.56 ± 16.33 ng/ml at 
0  min to 4.27 ±  0.91  ng/ml at 5  min. Plasma gas treat-
ment for 15  min led to 5.60  ±  1.14  ng/ml of Stx1 and 
6.18 ± 3.38 ng/ml of Stx2, whereas that for 30 min led to 
6.03 ± 1.84 ng/ml of Stx1 and 3.71 ± 1.13 ng/ml of Stx2. 
Thus, the concentration of Stx1 and Stx2 at 5, 15, and 
30  min was almost at the detection limit of the ELISA 
assay.
Western blotting was also performed to investigate the 
effect of nitrogen gas plasma on Stx1 and Stx2 (Fig.  3). 
This analysis showed that the band corresponding to 
the A subunit of Stx1 (approximately 35  kDa) and Stx2 
(approximately 35  kDa) (Russo et  al. 2014) diminished 
after nitrogen gas plasma treatment for 5, 15, and 30 min, 
as compared with that of the untreated sample (0 min).
The observation of Stx1 degradation by gas plasma 
treatment was further supported by a cell assay (Fig. 4). 
Because Stx1 and Stx2 have cytotoxic activity against 
HEp-2 cells, the change in cell viability after incubation 
with the treated samples was used as an index of the 
activity of Stx1 and Stx2. The viability of cells incubated 
with untreated Stx1 (0  min in Fig.  4a) and Stx2 (0  min 
in Fig.  4b) was lower than that of cells incubated with 
gas plasma-treated samples, suggesting that the cyto-
toxic activity of Stx1 and Stx2 was reduced by increasing 
plasma treatment. Notably, cells incubated with samples 
subjected to gas plasma treatment for 30  min showed 
significantly higher viability as compared with cells incu-
bated with untreated samples (p < 0.05 for Stx1; p < 0.01 
for Stx2). Therefore, nitrogen gas plasma treatment 
Fig. 2 Quantitative measurement of Stx1 and Stx2 by an enzyme-linked immunosorbent assay (ELISA) after nitrogen gas plasma treatment. A 
coverslip containing dried spots from 20 μl aliquots of a 1 μg/ml solution of Stx1 (a) and Stx2 (b) was treated with nitrogen gas plasma using 
BLP-TES device (1.5 kpps) for 0, 5, 15, and 30 min. The recovered samples were subjected to ELISA using  RIDASCREEN® Verotoxin (R-Biopharm AG, 
Darmstadt, Germany) to quantify Stx1 and Stx2. Values were considered significantly different from the untreated control (0 min) when verified by 
non-repeated measures ANOVA, followed by the Bonferroni correction (**p < 0.01)
Fig. 3 Western blotting of Stx1 and Stx2 after nitrogen gas plasma treatment. A coverslip containing dried spots from 20 μl aliquots of a 1 μg/ml 
solution of Stx1 (a) and Stx2 (b) was treated with nitrogen gas plasma using BLP-TES device (1.5 kpps) for 0, 5, 15, or 30 min. The recovered samples 
were subjected to Western blotting using antibody recognizing the A subunit of Stx
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causes not only the degradation of Stx1 and Stx2, but also 
a reduction of their physiological activity.
Discussion
The potential use of physical methods to degrade Stx can 
be exploited to improve food safety. Here, the potential 
application of nitrogen gas plasma to degrade Stx has 
been studied using a BLP-TES device. The maximum 
temperature in the chamber box of the BLP-TES device 
was 42 °C at 5 min, 70 °C at 15 min, and 75 °C at 30 min 
(Sakudo et al. 2013b). Our study shows that during inac-
tivation of Stx1 and Stx2 by the BLP-TES device, the 
sample temperature did not increase above 80  °C even 
after prolonged exposure for 30  min. Burk et  al. (2003) 
previously showed that heat treatment above 80  °C for 
10  min can be used to inactivate Stx. A more recent 
study reported only a slight decrease in activity of Stx2 
after heat treatment at 60  °C for 1 h, although a signifi-
cant reduction in activity was observed after treatment at 
80 °C for 1 h (He et al. 2012). As the effective temperature 
for inactivation is close that seen during gas plasma treat-
ment using the BLP-TES device, detailed quantitative and 
comparative studies are required to ascertain whether the 
inactivation mechanism of the gas plasma involves heat.
However, so far, the main mechanism of inactivation 
using the nitrogen gas plasma system of the BLP-TES 
device does not appear to involve exposure of the sam-
ple to elevated temperatures. A previous observation 
has suggested that the conformational changes in a pro-
tein induced by the nitrogen gas plasma are mediated 
by mechanisms distinct from those of heat degradation 
(Sakudo et al. 2013a). Because Stx1 and Stx2 are proteins, 
the conformational changes and degradation caused by 
the gas plasma may play important roles in their inactiva-
tion. In addition, the use of a more sensitive cell assay for 
Stx would be likely to detect the inactivating effect of the 
gas plasma on Stx at an earlier treatment time, because 
efficient degradation of Stx1 and Stx2 within 5 or 15 min 
of treatment was shown by all biochemical assays, includ-
ing immunochromatography, ELISA, and Western blot-
ting. Thus, further analysis using sensitive bioassays is 
required.
The Stx1 and Stx2 antibodies used in the Western blot-
ting analysis recognize the A subunit of each toxin. The 
Western blotting data therefore suggest that the nitro-
gen gas plasma degrades the A subunit of Stx, which is 
known to elicit its toxic activity. Therefore, some factors 
generated during operation of the BLP-TES device such 
as the production of reactive chemical species, which 
have previously been shown to be the principal contrib-
uting reason for the inactivation of bacteria and viruses 
(Maeda et al. 2015; Sakudo et al. 2017), may be respon-
sible for degrading Stx and their A subunits. Additional 
clarification of the mechanisms by which nitrogen gas 
plasma degrades Stx are required. Furthermore, in the 
present study, effective degradation of Stx was observed 
when a coverslip was used as the surface matrix during 
gas plasma treatment. Because the degradation efficiency 
and mechanisms may depend on the materials used for 
the surface matrix, further studies using other surface 
materials should be performed.
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